Advanced Solid Tumors, Excluding Breast Cancer
Conditions
Brief summary
This is a multi-center, open-label, single-sequence, crossover, drug-drug interaction (DDI) study to assess the effect of the CYP1A2 inhibitor, fluvoxamine, on the PK of dovitinib in patients with advanced solid tumors, excluding breast cancer. The purpose of this study is to evaluate the effect of a CYP1A2 inhibitor, 100 mg fluvoxamine, on the PK of dovitinib when administered at a dose of 300 mg on the dosing schedule, 5 days on/2 days off. The study will consist of 2 phases: a Pharmacokinetic (PK) phase and a clinical treatment phase. The DDI test will be conducted in the PK phase. The DDI test will assess the steady state PK profile of dovitinib when administered alone and in the presence of the CYP1A2 inhibitor, fluvoxamine (AUC 0-24h, AUC 0-72h and Cmax parameters). During the clinical treatment phase patients may continue to receive treatment with TKI258 until disease progression (assessed by RECIST 1.1), unacceptable toxicity, death or discontinuation from the study treatment for any other reason.
Interventions
DRUGfluvoxamine
perpetrator drug; 7 days of dosing
Sponsors
Novartis Pharmaceuticals
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Patients with a cytopathologically or histopathologically confirmed diagnosis of an advanced solid tumor, excluding breast cancer which has progressed despite standard therapy or for which no standard therapy exists - ECOG performance status 0 or 1 and an anticipated life expectancy of ≥3 months- Patient must meet protocol-specific laboratory values
Exclusion criteria
\- Patients with brain metastases - Patients who have received or who are expected to receive any prohibited medications and therapies - Patients who have received CYP1A2 or CYP3A inhibitor medications within 5 days prior to start study treatment or are expected to receive during the first 28 days after starting the study treatment - Patients who have received CYP1A2 or CYP3A inducer medications within 30 days prior to start study treatment or are expected to receive during the first 28 days after starting the study treatment - Patients who are actively taking antidepressants, benzodiazepines, serotonergic drugs, and/or monoamine oxidase inhibitors (MAOIs) - Patients who have not recovered from previous anti-cancer therapies - Patient with impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of TKI258 - Patients who have concurrent severe and/or uncontrolled concomitant medical conditions that could compromise participation in the study - Female patients who are pregnant or breast-feeding - Fertile males or women not willing to use highly effective methods of contraception - Other protocol-defined inclusion/
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| TKI258 pharmacokinetics (PK) parameters: Vz/F (apparent volume of distribution) | multiple time-points over 72h post dose on day Day 19 and Day 26 (PK phase) |
| TKI258 pharmacokinetics (PK) parameters: Tmax (Time to maximum concentration) | multiple time-points over 72h post dose on day Day 19 and Day 26 (PK phase) |
| TKI258 pharmacokinetics (PK) parameters: T1/2 (Half-life time) | multiple time-points over 72h post dose on day Day 19 and Day 26 (PK phase) |
| TKI258 pharmacokinetics (PK) parameters: CL/F (Apparent Oral Clearance) | multiple time-points over 72h post dose on day Day 19 and Day 26 (PK phase) |
| TKI258 pharmacokinetics (PK) parameters: Cmax (Maximum (peak) concentration of drug) | multiple time-points over 72h post dose on day Day 19 and Day 26 (PK phase) |
| TKI258 pharmacokinetics (PK) parameters: AUC 0-24 hr (Area Under the Curve) | multiple time-points over 72h post dose on day Day 19 and Day 26 (PK phase) |
| TKI258 pharmacokinetics (PK) parameters: AUC 0-72 hr | multiple time-points over 72h post dose on day Day 19 and Day 26 (PK phase) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Frequency and severity of SAEs (Serious Adverse Events) | up to at least 30 days after the last dose of dovitinib (TKI258) | — |
| Preliminary evidence of antitumor activity of dovitinib (TKI258) | every 8 weeks until progression of disease | overall response based on investigator assessment and best overall response using RECIST 1.1 |
| Frequency and severity of AEs (Adverse Events) | up to at least 30 days after the last dose of dovitinib (TKI258) | — |
Countries
Denmark, Netherlands, Switzerland, United States
Outcome results
None listed